Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

Inclusion Criteria: * Written informed consent prior to any study-related procedure not part of normal medical care; * Male or female ≥ 18 years of age; * If female of childbearing potential; willing to practice reliable birth control measures during study treatment and for at least 28 days after study completion, not lactating or pregnant, and has a documented negative pregnancy test result within 24 hours prior to study medication administration; * End-stage renal disease on stable (for at least 2 weeks) hemodialysis regimen, three times weekly using high-flux membranes; * Functioning hemodialysis access (for example, graft or fistula); * Considered to be in appropriate health for study entry by the Investigator (for example, no acute, debilitating medical problems) and appropriate candidate for completing study treatment; * If taking concomitant medications, subject must be on a relatively stable dose for at least two weeks prior to study drug administration. Exclusion Criteria: * Received an investigational drug (including experimental biologic agents) within 30 days of study drug administration; * Has received any dose of daptomycin within 7 days prior to study drug administration; * Known to be allergic or intolerant to daptomycin; * Evidence of active ongoing infection; * Known human immunodeficiency virus (HIV) infection with CD4 count ≤ 200 cells/mm3; * Active illicit drug use or alcohol abuse; * Myocardial infarction within last 6 months; * Subject with a history of muscular disease (for example, polymyositis, muscular dystrophy); * Subject with a history of neurological disease (for example, Guillain Barré, multiple sclerosis), except stroke \> 6 months prior to study entry; * Intramuscular injection within 7 days of study drug administration; * Body mass index (BMI) ≤ 18.5 or ≥ 40 kg/m2 (BMI = weight \[kg\]/height \[m2\]); * WBC ≥ 12, 000 cells/mm3 or ≤ 2500 cells/ mm3; * Neutropenic subject with absolute neutrophil count ≤ 500 cells/mm3; * Baseline CPK values ≥ 3X ULN (upper limit of normal); * Alanine aminotransferase (ALT) \> 5XULN; * Aspartate aminotransferase (AST) \> 5XULN; * Hemoglobin ≤ 9 gm/dL; * Is considered unlikely to comply with study procedures or to return for scheduled post-treatment evaluations; * History of rhabdomyolysis.